RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Aerie Pharmaceuticals Stock

Aerie Pharmaceuticals Revenue 2024

Aerie Pharmaceuticals Revenue

233.03 M USD

Ticker

AERI

ISIN

US00771V1089

WKN

A1W7RL

In 2024, Aerie Pharmaceuticals's sales reached 233.03 M USD, a 27.28% difference from the 183.08 M USD sales recorded in the previous year.

The Aerie Pharmaceuticals Revenue history

YEARREVENUE (undefined USD)GROSS MARGIN (%)
2026e384.2643,53
2025e296.2956,46
2024e233.0371,79
2023e183.0891,38
2022e138.59120,71
2021194.1386,17
202083.1469,53
201969.8993,09
201824.1897,35
2017--
2016--
2015--
2014--
2013--
2012--
2011--

Aerie Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Aerie Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Aerie Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Aerie Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Aerie Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Aerie Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Aerie Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Aerie Pharmaceuticals’s growth potential.

Aerie Pharmaceuticals Revenue, EBIT and net profit per share

DateAerie Pharmaceuticals RevenueAerie Pharmaceuticals EBITAerie Pharmaceuticals Net Income
2026e384.26 M undefined-18.93 M undefined-36.34 M undefined
2025e296.29 M undefined-11.57 M undefined-22.95 M undefined
2024e233.03 M undefined-7.21 M undefined-14.79 M undefined
2023e183.08 M undefined-54.53 M undefined-63.73 M undefined
2022e138.59 M undefined-91.82 M undefined-105.98 M undefined
2021194.13 M undefined-46.35 M undefined-74.81 M undefined
202083.14 M undefined-155.69 M undefined-183.1 M undefined
201969.89 M undefined-187.49 M undefined-199.58 M undefined
201824.18 M undefined-209.74 M undefined-232.57 M undefined
20170 undefined-145.69 M undefined-145.11 M undefined
20160 undefined-96.87 M undefined-99.06 M undefined
20150 undefined-75.09 M undefined-74.36 M undefined
20140 undefined-49.97 M undefined-48.13 M undefined
20130 undefined-22.17 M undefined-31.6 M undefined
20120 undefined-14.29 M undefined-15.64 M undefined
20110 undefined-14.22 M undefined-13.42 M undefined

Aerie Pharmaceuticals stock margins

The Aerie Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Aerie Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Aerie Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Aerie Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Aerie Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Aerie Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Aerie Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Aerie Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Aerie Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Aerie Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Aerie Pharmaceuticals Margin History

Aerie Pharmaceuticals Gross marginAerie Pharmaceuticals Profit marginAerie Pharmaceuticals EBIT marginAerie Pharmaceuticals Profit margin
2026e86.17 %-4.93 %-9.46 %
2025e86.17 %-3.9 %-7.75 %
2024e86.17 %-3.09 %-6.35 %
2023e86.17 %-29.78 %-34.81 %
2022e86.17 %-66.25 %-76.47 %
202186.17 %-23.88 %-38.54 %
202069.53 %-187.26 %-220.23 %
201993.09 %-268.26 %-285.56 %
201897.35 %-867.41 %-961.83 %
201786.17 %0 %0 %
201686.17 %0 %0 %
201586.17 %0 %0 %
201486.17 %0 %0 %
201386.17 %0 %0 %
201286.17 %0 %0 %
201186.17 %0 %0 %

Aerie Pharmaceuticals Aktienanalyse

What does Aerie Pharmaceuticals do?

Aerie Pharmaceuticals Inc is a US-based company specializing in the development of drugs for the treatment of eye diseases. The company was founded in 2005 by David Epstein and is headquartered in Durham, North Carolina. Aerie Pharmaceuticals aims to use innovative thinking and the latest technologies to improve the treatment of eye diseases and enhance the lives of people worldwide. They have developed several drugs that are already available on the market. Their main focus is on researching and developing eye medications, particularly those that can reduce intraocular pressure in patients with glaucoma. Their key drugs are Rhopressa and Rocklatan. In addition, they have plans to develop and market more products for the treatment of eye diseases. They collaborate with various partners including pharmaceutical distributors and pharmacies to bring their medications to the market globally. Overall, Aerie Pharmaceuticals is a leading provider of ophthalmic drugs and is dedicated to revolutionizing the treatment of eye diseases. Aerie Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Aerie Pharmaceuticals's Sales Figures

The sales figures of Aerie Pharmaceuticals originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Aerie Pharmaceuticals’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Aerie Pharmaceuticals's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Aerie Pharmaceuticals’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Aerie Pharmaceuticals stock

How much revenue did Aerie Pharmaceuticals generate this year?

Aerie Pharmaceuticals has achieved a revenue of 233.03 M USD this year.

How much was the turnover of the company Aerie Pharmaceuticals compared to the previous year?

The revenue of Aerie Pharmaceuticals has increased by 27.28% increased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Aerie Pharmaceuticals?

The revenue of Aerie Pharmaceuticals is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Aerie Pharmaceuticals measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Aerie Pharmaceuticals so important for investors?

The revenue of Aerie Pharmaceuticals is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Aerie Pharmaceuticals pay?

Over the past 12 months, Aerie Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Aerie Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Aerie Pharmaceuticals?

The current dividend yield of Aerie Pharmaceuticals is .

When does Aerie Pharmaceuticals pay dividends?

Aerie Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Aerie Pharmaceuticals?

Aerie Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Aerie Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Aerie Pharmaceuticals located?

Aerie Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Aerie Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Aerie Pharmaceuticals from 9/29/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/29/2024.

When did Aerie Pharmaceuticals pay the last dividend?

The last dividend was paid out on 9/29/2024.

What was the dividend of Aerie Pharmaceuticals in the year 2023?

In the year 2023, Aerie Pharmaceuticals distributed 0 USD as dividends.

In which currency does Aerie Pharmaceuticals pay out the dividend?

The dividends of Aerie Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Aerie Pharmaceuticals

Our stock analysis for Aerie Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Aerie Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.